CorMedix Inc. (FRA:19KA)

Market Cap	571.73M -34.4%
Revenue (ttm)	404.61M +280.5%
Net Income	162.82M +265.9%
EPS	1.82 +163.5%
Shares Out	n/a
PE Ratio	3.51
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Open	7.10
Previous Close	6.91
Day's Range	7.10 - 7.10
52-Week Range	5.20 - 12.70
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 13, 2026

About CorMedix

CorMedix Inc., a biopharmaceutical company, focuses on developing and commercializing therapeutic products for life-threatening diseases and conditions in the United States. Its lead product candidate is DefenCath, an antimicrobial catheter lock solution to reduce the incidence of catheter-related bloodstream infections in adult patients with kidney failure. CorMedix Inc. was formerly known as Picton Holding Company, Inc. and changed its name to CorMedix, Inc. in January 2007. The company was incorporated in 2006 and is based in Parsippany, New...

• Industry: Pharmaceutical Preparations
• Founded: 2006
• Employees: 191
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: 19KA

Financial Performance

Financial numbers in USD

Data Sources: S&P Global Market Intelligence and Twelve Data

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Twelve Data.

Last checked:

Aug 26, 2026

Data Sources Report a data error